ODT Odonate Therapeutics Inc

Price (delayed)

$3.52

Market cap

$135.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.76

Enterprise value

$6.87M

Highlights
The EPS has grown by 4.1% YoY and by 2.1% from the previous quarter
Odonate Therapeutics's debt has surged by 163% YoY but it has decreased by 2.4% QoQ
The quick ratio has contracted by 34% YoY and by 31% from the previous quarter
The equity has declined by 23% since the previous quarter and by 22% year-on-year

Key stats

What are the main financial stats of ODT
Market
Shares outstanding
38.51M
Market cap
$135.55M
Enterprise value
$6.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$129.96M
EBITDA
-$128.88M
Free cash flow
-$110.63M
Per share
EPS
-$3.76
Free cash flow per share
-$2.96
Book value per share
$2.73
Revenue per share
$0
TBVPS
$3.82
Balance sheet
Total assets
$142.88M
Total liabilities
$37.58M
Debt
$5.2M
Equity
$105.3M
Working capital
$103.01M
Liquidity
Debt to equity
0.05
Current ratio
4.11
Quick ratio
4.05
Net debt/EBITDA
1
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-80.9%
Return on equity
-101.4%
Return on invested capital
N/A
Return on capital employed
-118.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ODT stock price

How has the Odonate Therapeutics stock price performed over time
Intraday
-2.49%
1 week
-6.88%
1 month
5.71%
1 year
-91.85%
YTD
-81.67%
QTD
2.92%

Financial performance

How have Odonate Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$130.43M
Net income
-$129.96M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 15% YoY and by 2.9% from the previous quarter
ODT's operating income is down by 12% year-on-year and by 2.4% since the previous quarter

Growth

What is Odonate Therapeutics's growth rate over time

Valuation

What is Odonate Therapeutics stock price valuation
P/E
N/A
P/B
1.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 4.1% YoY and by 2.1% from the previous quarter
The P/B is 77% lower than the last 4 quarters average of 5.5
The equity has declined by 23% since the previous quarter and by 22% year-on-year

Efficiency

How efficient is Odonate Therapeutics business performance
ODT's return on equity has dropped by 51% year-on-year and by 9% since the previous quarter
ODT's ROA is down by 39% YoY and by 6% QoQ

Dividends

What is ODT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ODT.

Financial health

How did Odonate Therapeutics financials performed over time
Odonate Therapeutics's total liabilities has increased by 41% YoY and by 18% QoQ
Odonate Therapeutics's current ratio has decreased by 35% YoY and by 30% from the previous quarter
Odonate Therapeutics's debt is 95% lower than its equity
Odonate Therapeutics's debt has surged by 163% YoY but it has decreased by 2.4% QoQ
The debt to equity has increased by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.